Role of PCSK9 in lipid metabolism and atherosclerosis
Autor: | Xiao‑Long Lin, Mihua Liu, Zhi-Han Tang, Zhi-Sheng Jiang, Le-Le Xiao |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Statin medicine.drug_class Hypercholesterolemia Familial hypercholesterolemia 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Hyperlipidemia medicine Animals Humans cardiovascular diseases Cholesterol business.industry Anticholesteremic Agents PCSK9 nutritional and metabolic diseases Lipid metabolism Cholesterol LDL General Medicine Atherosclerosis Lipid Metabolism medicine.disease 030104 developmental biology chemistry Low-density lipoprotein LDL receptor lipids (amino acids peptides and proteins) Proprotein Convertase 9 business |
Zdroj: | Biomedicine & Pharmacotherapy. 104:36-44 |
ISSN: | 0753-3322 |
Popis: | Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new pharmacologically therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing LDLR degradation and preventing LDLR recirculation to the cell surface. Moreover, PCSK9 inhibitors have been approved for patients with either familial hypercholesterolemia or atherosclerotic cardiovascular disease, who require additional reduction of LDL-C. In addition, PCSK9 inhibition combined with statins has been used as a new approach to help reduce LDL-C levels in patients with either statin intolerance or unattainable LDL goal. This review will discuss the emerging anti-PCSK9 therapies in the regulation of cholesterol metabolism and atherosclerosis. |
Databáze: | OpenAIRE |
Externí odkaz: |